Abstract：
OBJECTIVE: The purpose of this meta-analysis is to evaluate the efficacy and safety of TAS-102 in treating metastatic colorectal cancer (mCRC) using the most recent data available.
METHODS: The literature on the efficacy and safety of TAS-102 versus placebo and/or best supportive care (BSC) in mCRC was obtained through a systematic search of PubMed, Embase, and Web of Science databases through January 2023. Identify the included literature and extract pertinent data, such as the overall survival (OS), progression-free survival (PFS), time to treatment failure (TTF), disease control rate (DCR), incidence of adverse events (AEs) and serious adverse events (SAEs).
RESULTS: There were eight eligible articles that included 2903 patients (1964 TAS-102 versus 939 Placebo and/or BSC). In this meta-analysis, TAS-102 treatment resulted in longer OS, PFS, TTF, and higher DCR in patients with mCRC versus placebo and/or BSC. TAS-102 improved OS and PFS in subgroup analyses of mCRC patients with KRAS wild-type and KRAS mutant-type. In addition, TAS-102 did not increase the incidence of serious adverse events.
CONCLUSIONS: TAS-102 can enhance the prognosis of mCRC patients whose standard therapy has failed, regardless of KRAS mutation status, and its safety is acceptable.
METHODS: The literature on the efficacy and safety of TAS-102 versus placebo and/or best supportive care (BSC) in mCRC was obtained through a systematic search of PubMed, Embase, and Web of Science databases through January 2023. Identify the included literature and extract pertinent data, such as the overall survival (OS), progression-free survival (PFS), time to treatment failure (TTF), disease control rate (DCR), incidence of adverse events (AEs) and serious adverse events (SAEs).
RESULTS: There were eight eligible articles that included 2903 patients (1964 TAS-102 versus 939 Placebo and/or BSC). In this meta-analysis, TAS-102 treatment resulted in longer OS, PFS, TTF, and higher DCR in patients with mCRC versus placebo and/or BSC. TAS-102 improved OS and PFS in subgroup analyses of mCRC patients with KRAS wild-type and KRAS mutant-type. In addition, TAS-102 did not increase the incidence of serious adverse events.
CONCLUSIONS: TAS-102 can enhance the prognosis of mCRC patients whose standard therapy has failed, regardless of KRAS mutation status, and its safety is acceptable.
摘要：
目的：本荟萃分析的目的是利用现有的最新数据评估TAS-102治疗转移性结直肠癌（mCRC）的有效性和安全性。
方法：关于TAS-102与安慰剂和/或最佳支持治疗（BSC）在mCRC中的疗效和安全性的文献是通过对PubMed的系统搜索获得的，Embase,和WebofScience数据库到2023年1月。确定所包含的文献并提取相关数据，例如总生存期(OS)，无进展生存期（PFS），治疗失败时间（TTF），疾病控制率（DCR），不良事件（AE）和严重不良事件（SAE）的发生率。
结果：有8篇符合条件的文章包括2903名患者（1964年TAS-102对939名安慰剂和/或BSC）。在这个荟萃分析中，TAS-102治疗导致更长的OS，PFS,TTF,与安慰剂和/或BSC相比，mCRC患者的DCR更高。TAS-102在KRAS野生型和KRAS突变型mCRC患者亚组分析中改善OS和PFS。此外,TAS-102没有增加严重不良事件的发生率。
结论：TAS-102可以提高标准治疗失败的mCRC患者的预后，无论KRAS突变状态如何，它的安全性是可以接受的。
方法：关于TAS-102与安慰剂和/或最佳支持治疗（BSC）在mCRC中的疗效和安全性的文献是通过对PubMed的系统搜索获得的，Embase,和WebofScience数据库到2023年1月。确定所包含的文献并提取相关数据，例如总生存期(OS)，无进展生存期（PFS），治疗失败时间（TTF），疾病控制率（DCR），不良事件（AE）和严重不良事件（SAE）的发生率。
结果：有8篇符合条件的文章包括2903名患者（1964年TAS-102对939名安慰剂和/或BSC）。在这个荟萃分析中，TAS-102治疗导致更长的OS，PFS,TTF,与安慰剂和/或BSC相比，mCRC患者的DCR更高。TAS-102在KRAS野生型和KRAS突变型mCRC患者亚组分析中改善OS和PFS。此外,TAS-102没有增加严重不良事件的发生率。
结论：TAS-102可以提高标准治疗失败的mCRC患者的预后，无论KRAS突变状态如何，它的安全性是可以接受的。
